Mumbai, Montreal, February 16, 2026: Global pharma major Lupin Limited (Lupin), today announced that it has signed a licence and supply agreement with Spektus Pharma (Spektus), a specialty pharmaceutical company to commercialize the novel antidepressant DeslaFlex™ in Canada.
DeslaFlex™ is an innovative antidepressant formulation developed by Spektus using the proprietary Flexitab™ oral drug-delivery platform.
This strategic partnership combines Lupin’s strong commercial footprint in Canada and Spektus’s capabilities in developing differentiated, novel formulations to successfully introduce DeslaFlex™ and establish a robust platform for future launches. The collaboration further strengthens Lupin’s CNS portfolio with physician-endorsed, value-added therapies, well aligned with a supportive regulatory environment.
“This milestone reinforces our long-term commitment to advancing Lupin’s CNS footprint and deepens our commitment to Canadian healthcare. The addition of DeslaFlex™ to our portfolio provides patients and clinicians with much-needed flexibility in the management of Major Depressive Disorder, enabling clinicians to deliver more personalized, patient-focused care,” said Claus Jepsen, President, Global Specialty, Lupin.
Zarvaan Merchant, Chief Executive Officer of Spektus Pharma, said, “This partnership with Lupin represents a key milestone as Spektus transitions from development to commercial execution. Lupin’s global brand and established commercial strength in Canada make it an ideal partner to realize the full value of DeslaFlex™ for patients across this important market.”
About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin
About Spektus Pharma
Spektus Pharma is a growth-stage pharmaceutical company focused on developing and commercializing value-added CNS therapies. Using its proprietary drug-delivery platforms such as Flexitab™ and AmyloFlex™, the company unlocks clinically relevant advantages for established molecules — including enhanced dosing flexibility, improved patient compliance, and expanded label opportunities — addressing unmet needs across depression, pain, and ADHD. Headquartered in Laval, Quebec, Spektus leverages a global partner network to bring these optimized medicines to patients worldwide. For more information, visit www.spektuspharma.com
For further information or queries, please contact
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin
rajalakshmiazariah@lupin.com
*Safe Harbor Statement
